Ann: First-in-human study update - First patient enrolled, page-114

It good that we are collaborating with Patrys

From the ASX Announcement 3 May 21

Patrys and Imagion Biosystems to collaborate on
brain tumor imaging
Melbourne, Australia; 3 May 2021: Patrys Limited (ASX: PAB, “Patrys”), a therapeutic antibody
development company, and Imagion Biosystems Limited (ASX: IBX), a company dedicated to
improving healthcare through the earlier detection of cancer, are pleased to announce a collaborative
research program using their combined technologies to improve brain tumor imaging and diagnosis.

“We are very interested in the tumor targeting capabilities of the Patrys deoxymabs and believe
there is potential for Patrys’ deoxymabs to be paired with our MagSense® nanoparticles for many
types of solid tumors,” said Bob Proulx, Executive Chairman of Imagion Biosystems. “Initially, we
are very keen to investigate the potential for brain tumor imaging since there is such a high unmet
need for differentiating cancerous tumors in the brain, like glioblastoma, as well as metastatic
disease that has spread to the brain from other primary tumors.”

Preliminary research efforts by Imagion have demonstrated that the Patrys PAT-DX1 molecule can be
conjugated to the MagSense® nanoparticles and provide bio-functionality for targeting certain cancer
cell lines. Should this further collaborative work provide positive results, Imagion will have an
exclusive option to a future license agreement, should it elect to commercialize the imaging
agent.